These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 18482778

  • 1. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M, López-Galíndez C.
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [Abstract] [Full Text] [Related]

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 3. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, Liao Q, Hirani A, Graham N, St Clair M, Hernandez J, NZT40012 Study Team.
    AIDS Res Hum Retroviruses; 2001 Aug 10; 17(12):1107-15. PubMed ID: 11522180
    [Abstract] [Full Text] [Related]

  • 4. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH.
    J Virol; 2004 Sep 10; 78(18):9987-97. PubMed ID: 15331732
    [Abstract] [Full Text] [Related]

  • 5. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Reid P, MacInnes H, Cong ME, Heneine W, García-Lerma JG.
    Virology; 2005 Jun 05; 336(2):251-64. PubMed ID: 15892966
    [Abstract] [Full Text] [Related]

  • 6. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G.
    Antiviral Res; 2007 Nov 05; 76(2):99-103. PubMed ID: 17640745
    [Abstract] [Full Text] [Related]

  • 7. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.
    Virology; 2001 May 10; 283(2):294-305. PubMed ID: 11336554
    [Abstract] [Full Text] [Related]

  • 8. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
    García-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W.
    J Virol; 2003 May 10; 77(10):5685-93. PubMed ID: 12719561
    [Abstract] [Full Text] [Related]

  • 9. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.
    Antiviral Res; 2006 Jun 10; 70(2):66-74. PubMed ID: 16472877
    [Abstract] [Full Text] [Related]

  • 10. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, Martinez-Picado J.
    Virology; 2004 Aug 15; 326(1):103-12. PubMed ID: 15262499
    [Abstract] [Full Text] [Related]

  • 11. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY, Johns DG, Tanaka M, Mitsuya H.
    Mol Pharmacol; 1999 Mar 15; 55(3):535-40. PubMed ID: 10051538
    [Abstract] [Full Text] [Related]

  • 12. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N, Plyasunova O, Kiseleva Y, Fedyuk N, Pokrovsky A.
    Nucleosides Nucleotides Nucleic Acids; 2003 Mar 15; 22(5-8):991-4. PubMed ID: 14565328
    [Abstract] [Full Text] [Related]

  • 13. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M, Mendieta J, Puertas MC, Parera M, Martínez MA, Martinez-Picado J, Menéndez-Arias L.
    J Mol Biol; 2008 Oct 03; 382(2):327-41. PubMed ID: 18662701
    [Abstract] [Full Text] [Related]

  • 14. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE, Franco S, Martínez MA, Menéndez-Arias L.
    J Mol Biol; 2007 Jan 12; 365(2):298-309. PubMed ID: 17070543
    [Abstract] [Full Text] [Related]

  • 15. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
    Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M.
    J Infect Dis; 2002 Apr 01; 185(7):898-904. PubMed ID: 11920313
    [Abstract] [Full Text] [Related]

  • 16. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ, Chappey C, Parkin NT, Miller MD.
    Antivir Ther; 2008 Apr 01; 13(2):189-97. PubMed ID: 18505170
    [Abstract] [Full Text] [Related]

  • 17. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J.
    J Med Virol; 2007 Feb 01; 79(2):127-37. PubMed ID: 17177310
    [Abstract] [Full Text] [Related]

  • 18. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, Mitsuya H, Kimura S, Oka S.
    Virology; 2004 Oct 01; 327(2):215-24. PubMed ID: 15351209
    [Abstract] [Full Text] [Related]

  • 19. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, McLean M, Krishnamurthy A, DeVlaming S, Conway B.
    Int J Infect Dis; 2009 Sep 01; 13(5):577-83. PubMed ID: 19111493
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG, Nidtha S, Heneine W.
    J Infect Dis; 2001 Aug 15; 184(4):507-10. PubMed ID: 11471110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.